Simethicone administration improves efficacy and efficiency of esophagogastroduodenoscopy

**CURRENT STATUS:** POSTED

Xiaotian Sun  
Chinese People's Liberation Army Hospital 307  
xiaotian-sun@hotmail.com  
**Corresponding Author**  
ORCiD: https://orcid.org/0000-0003-4425-0442

Yang Xu  
Chinese PLA General Hospital

Xueting Zhang  
Chinese PLA General Hospital

Cuiyun Ma  
PLA Army General Hospital

Aitong Li  
Chinese PLA General Hospital

Haiyan Yu  
Chinese PLA General Hospital

Weihua Zhang  
Chinese PLA General Hospital

Hanqing Zhang  
Chinese PLA General Hospital

Teng Yang  
Chinese PLA General Hospital

Shengzhou Zu  
Chinese PLA General Hospital

Yan Liu  
Chinese PLA General Hospital
Abstract

Background: Esophagogastroduodenoscopy is very useful in diagnosing and treating upper gastrointestinal mucosal disorders, but too much foam and water in stomach decrease its diagnostic efficiency. Simethicone administration can help remove excessive foam. Aims: To determine the optimal simethicone administration strategies in a comparative randomized controlled clinical trial.

Methods: Adult outpatients with indications for esophagogastroduodenoscopy were enrolled and randomly divided into Group 1 (simethicone solution intake 20-30 min before procedure, n=110), Group 2 (simethicone solution intake 31-60 min before procedure, n=92) and Group 3 (simethicone solution intake >60 min before procedure). Primary and secondary outcome were procedure time and the patients’ satisfaction after the examination. All symptoms like abdominal pain, distension were recorded.

Results: No statistically significant differences were found on the patients’ demographic and clinical features, and mean examination time (all P values >0.05). The distribution of patients with different endoscopic and pathological diagnosis was comparable among three groups, respectively (P=0.607; P=0.289). However, the proportion of patients with Gastric Cleanness Grade A was most in Group 2 (n=73, 79.3%), and patient proportion with Gastric Cleanness Grade C was most found in Group 1 (n=72, 65.5%), which was greatly different (P<0.001). There was no statistically significant difference on the satisfaction scores [immediately 6 (3-8) vs. 6 (1-10) vs. 6 (1-9), P=0.533; 2h after 10 (8-10) vs. 10 (10-10) vs. 10 (8-10), P=0.463].

Conclusion: Simethicone solution intake 31-60 min before esophagogastroduodenoscopy can help obtain best gastric cleanness, which is recommended in clinical practice (registered at ClinicalTrials.gov, NCT03776916).

What Is Known?
The presence of too much foam and water in the stomach limited esophagogastroduodenoscopy’s value in managing upper gastrointestinal mucosal disorders. Simethicone can remove excessive foam, while its optimal administration strategy has not been examined.

What Is New Here?
Simethicone solution intake 31-60 min before esophagogastroduodenoscopy can effectively help
obtain the best gastric cleanness for upper gastrointestinal endoscopy, which can be recommended as a routine in clinical practice.

Introduction
Esophagogastroduodenoscopy is well acknowledged as the most useful tool for diagnosing and treating upper gastrointestinal tract mucosal lesions [1-2]. It has the advantage of directly observing the esophageal, gastric and duodenal mucosa and obtaining biopsy of the potential lesions for pathological examination, thus being widely applied in clinical practice all over the world [3-5]. However, during the examination, too much water, mucus, foam or residues in the stomach will not only increase the procedure time and the misdiagnosis rate, but also decrease the patients’ tolerance, so more efforts should be made to avoid excessive water, mucus, foam or residues in order to get a clear view of the upper gastrointestinal tract mucosa.

Simethicone is also called poly-dimethylsiloxane, which has been introduced to remove the foam and water. Recent studies have reported that the administration of simethicone before endoscopic examination could shorten the procedure time and improve the diagnostic rate of the gastric mucosal lesions [6-7]. Although simethicone has been routinely administrated before the esophagogastroduodenoscopy, the optimal strategy of administrating simethicone has not been clearly investigated, especially the time interval from simethicone administration to the endoscopic procedure. Too late intake of simethicone will result in too excessive water in the stomach due to the insufficient time for the stomach to empty, while if the patients take it too early it doesn’t take effects. Thus, we conducted this randomized controlled clinical trial aiming to optimize the current simethicone administration strategies and these results could improve the performance of the esophagogastroduodenoscopy and minimize the patients’ dissatisfaction. Different simethicone administration strategies for esophagogastroduodenoscopy were compared and whether the time of taking simethicone before endoscopy could influence the efficacy and efficiency of the endoscopic examination was tested, which may benefit the identification of a standardized protocol for endoscopic procedures.

Patients And Methods
Patients

Adult outpatients with the indications for esophagogastroduodenoscopy who agreed to participate in the study in Endoscopy Center of the Fifth Medical Center of Chinese PLA General Hospital from December 17, 2018 to March 17, 2019 were included. Patients who were receiving nonsteroidal anti-inflammatory drugs, pump inhibitors (PPI) or antibiotics in the last 3 weeks, or had severe uncontrolled coagulopathy, prior history of gastric surgery, or were pregnant and lactation were excluded. All the patients signed written informed consent.

Study design and grouping

The flow chart was shown in Figure 1. This study was registered at ClinicalTrials.gov on Dec 13, 2018 and the registration number was NCT03776916. The protocol was approved by the ethic committee of Affiliated Hospital to Academy of Military Medical Sciences (the Fifth Medical Center of Chinese PLA General Hospital) on Oct 12, 2018.

The sample size was calculated to reveal a difference on the gastric cleanness among different groups, keeping a power of 0.9 and significance level alpha of 0.05. The sample size was estimated to be 300. All the patients were randomly divided into three experimental groups using random number method: Group 1 (simethicone solution intake 20-30 min before the procedure), Group 2 (simethicone solution intake 31-60 min before the procedure) and Group 3 (simethicone solution intake >60 min before the procedure).

Esophagogastroduodenoscopy

All endoscopic procedures were completed by one experienced expert endoscopist who had an endoscopy experience of over 5 years. No patients underwent propofol sedation. EG-L590WR endoscopes equipped with the LASEREO endoscopic system (FUJIFILM Co., Tokyo, Japan) were used. The gastric cleanness was evaluated by the endoscopist as Gastric Cleanness Grade and categorized into 3 grades based on the findings of the stomach (Figure 2). All the endoscopic images taken during the esophagogastroduodenoscopy were evaluated and the percentage of water and foam in each image was assessed as a subjective evaluator for Gastric Cleanness Grade. After the procedure, all patients were routinely monitored for 1 hour.
Outcomes

Primary outcome was procedure time. The time of examining the whole stomach was recorded, and the time for biopsy was not included. Secondary outcome was the patients' satisfaction after the examination. A 10-point scale was used to evaluate the patients’ satisfaction (0 worst, 10 best). All the symptoms such as abdominal pain, distension and the like were also recorded.

Statistical analysis

All the statistical analysis was performed using SPSS software. The continuous and categorical data were presented as mean (range) and percentage, respectively. The differences among three groups were tested by one-way analysis of variance (ANOVA) and chi-square if applicable. A two-tailed P value less than 0.05 was considered as statistically significant.

Results

Demographic and clinical characteristics

A total of 311 patients were included for analysis, including 110 in Group 1, 92 in Group 2 and 109 in Group 3. There were no statistically significant differences on the demographic (age and gender) and clinical features (previous esophagogastroendoscopy history, indications for endoscopic examinations and positive H. pylori infection within 3 months) (all P values >0.05) (Table 1).

Endoscopic examinations

The distribution of patients with different endoscopic and pathological diagnosis was comparable among the three groups, respectively (P=0.607; P=0.289) (Table 2). The mean examination time in Group 1, 2 and 3 was 8 (2-20), 6 (2-15) and 9 (2-25) min, which was not greatly different (P=0.267). However, statistically significant differences were found on gastric cleanness grade (P<0.001) (Table 2). The proportion of patients with Gastric Cleanness Grade A was most in Group 2 (n=73, 79.3%), followed by Group 3 (n=29, 26.6%) and then Group 1 (n=19, 17.3%). Patient proportion with Gastric Cleanness Grade C was most found in Group 1 (n=72, 65.5%), followed by Group 3 (n=39, 35.8%) and Group 2 (n=7, 7.6%).

Patients’ satisfaction

Satisfaction score was reported by the patients immediately and 2h after the endoscopic
examinations, but there was no statistically significant difference on the satisfaction scores [6 (3-8) vs. 6 (1-10) vs. 6 (1-9), P=0.533; 10 (8-10) vs. 10 (10-10) vs. 10 (8-10), P=0.463] (Table 3). For discomfort reported immediately after the endoscopy, 38 patients (34.5%) in Group 1, 23 patients (25.0%) in Group 2 and 29 patients (26.6%) in Group 3 complained the presence of abdominal distension (P=0.264). Thirteen patients (11.8%) in Group 1, 8 patients (8.7%) in Group 2 and 6 patients (5.5%) in Group 3 had nausea (P=0.252). In Group 1, 24.54% patients (n=27) had throat pain, which was 2.2% (n=2) in Group 2 and 10.8% (n=10) in Group 3 (P<0.001) (Table 3).

Discussion

Esophagogastroduodenoscopy is the most useful tool for diagnosing and treating upper gastrointestinal mucosal lesions. At recent, great progress has been made on improving the efficiency and accuracy of the endoscopic procedures [8]. It is reported that the administration of simethicone before esophagogastroduodenoscopy can increase the detection rate of the lesions by removing the foams in the stomach [9]. However, the optimal strategy of simethicone usage has not been well clarified. Thus, in this study we aimed to investigate the influence of different simethicone administration strategies on the gastric cleanness for esophagogastroduodenoscopy.

Sajid MS et al ever conducted a systematic review and meta-analysis of 7 randomized controlled trials on the application of simethicone in improving the gastric mucosal visualization during esophagogastroduodenoscopy [9]. These results supported that oral simethicone administration before endoscopic examinations can improve the mucosal visualization of the stomach. Mucosal visibility score was reported in four trials, and the other three trials reported the number of patients with adequate and poor visibility [10–16]. In our present study, we defined Gastric Cleanness Grade based on the observation of the water and foam in gastric body and fundus under endoscopy, which was manifested in Fig. 2. Gastric Cleanness Grade was used to evaluate the effectiveness of simethicone in cleaning the stomach for observation under endoscopy. Our data showed that the percentage of patients with Gastric Cleanness Grade A was highest in Group 2 (simethicone solution intake 31–60 min before the procedure), which was obviously higher than those in Group 1 and 3 (79.3% vs. 17.3% and 26.6%, P < 0.001). It was proved that simethicone solution intake 31–60 min
before the procedure can obtain the best gastric visualization for endoscopic procedures, compared with pre-procedural simethicone solution intake 20–30 min and > 60 min before.

No significant differences were found on patients’ satisfaction score both immediately and 2 h after the procedure (both P values > 0.05), indicating that all the three simethicone intake methods were all tolerated by the patients. The incidence of symptoms reported by the patients were nearly comparable among different groups, except throat pain. Group 1 had a greatly higher percentage of patients (24.5%, n = 27) who had throat pain than 2.2% (n = 2) in Group 2 and 10.8% (n = 10) in Group 3 (P < 0.001). This may be partly explained by the repeated friction between endoscopy body and the pharyngeal mucosa in Group 1 in order to remove the excessive water or foam in the stomach, which was consistent with the fact that the examination time in Group 1 was a bit longer than that in Group 2 but shorter than that in Group 3 although the difference was not obviously significant [8 (2–20), 6 (2–15) and 9 (2–25) min; P = 0.267].

There were also limitations in this study. First, all the patients were included from one single center. Second, only selected demographic and clinical variables were analyzed here, and some other potential factors that may influence gastric mucosal visualization like dietary lifestyle were not investigated. Third, we did not examine the effect of simethicone combined with N-acetylcysteine, because N-acetylcysteine was not routinely used in our endoscopy center.

In summary, simethicone solution intake 31–60 min before the procedure is suggested, which can be introduced as a routine standard pre-procedural preparation for good quality esophagastroduodenoscopy, especially for those patients with suspected malignant upper gastrointestinal lesions. Additionally, this conclusion will be further validated in a large multi-center randomized clinical trial.

Declarations

Compliance with Ethical Standards

- Disclosure of potential conflicts of interest: None.
- Research involving Human Participants and/or Animals: Human Participants.
- Informed consent: All the patients gave their written informed consent.
References
1. Ebigbo A, Messmann H, Rommele C. Endoscopic Upper GI Screening. Visc Med 2019 Aug;35(4):240-244.
2. Emura F, Rodriguez-Reyes C, Giraldo-Cadavid L. Early Gastric Cancer: Current Limitations and What Can Be Done to Address Them. Am J Gastroenterol. 2019 Jun;114(6):841-845.
3. Dohi O, Majima A, Naito Y, Yoshida T, Ishida T, Azuma Y, Kitae H, Matsumura S, Mizuno N, Yoshida N, Kamada K, Itoh Y. Can image-enhanced endoscopy improve the diagnosis of Kyoto classification of gastritis in the clinical setting? Dig Endosc. 2019 Sep.
4. Swager AF, van der Sommen F, Klomp SR, Zinger S, Meijer SL, Schoon EJ, Bergman JJGHM, de With PH, Curvers WL. Computer-aided detection of early Barrett's neoplasia using volumetric laser endomicroscopy. Gastrointest Endosc. 2017 Nov;86(5):839-846.
5. Mori Y, Kudo SE, Mohmed HEN, Misawa M, Ogata N, Itoh H, Oda M, Mori K. Artificial intelligence and upper gastrointestinal endoscopy: Current status and future perspective. Dig Endosc. 2019 Jul;31(4):378-388.
6. Devereaux BM, Taylor ACF, Athan E, Wallis DJ, Brown RR, Greig SM, Bailey FK, Vickery K, Wardle E, Jones DM. Simethicone use during gastrointestinal endoscopy: Position statement of the Gastroenterological Society of Australia. J Gastroenterol Hepatol. 2019 Jun 26.
7. Ofstead CL, Hopkins KM, Eiland JE, Wetzler HP. Widespread clinical use of simethicone, insoluble lubricants, and tissue glue during endoscopy: A call to action for infection preventionists. Am J Infect Control. 2019 Jun;47(6):666-670.8.
Bhandari P, Subramaniam S, East JE. British Society of Gastroenterology Endoscopy
Quality Improvement Programme (BSG EQIP): Implementing new endoscopic techniques and technologies into clinical practice. Frontline Gastroenterol. 2019 Apr;10(2):155-159.

9. Sajid MS, Rehman S, Chedgy F, Singh KK. Improving the mucosal visualization at gastroscopy: a systematic review and meta-analysis of randomized, controlled trials reporting the role of Simethicone ± N-acetylcysteine. Transl Gastroenterol Hepatol. 2018 May 19;3:29.

10. Asl SM, Sivandzadeh GR. Efficacy of premedication with activated Dimethicone or N-acetylcysteine in improving visibility during upper endoscopy. World J Gastroenterol. 2011 Oct 7;17(37):4213-7.

11. Basford PJ, Brown J, Gadeke L, Fogg C, Haysom-Newport B, Ogollah R, Bhattacharyya R, Longcroft-Wheaton G, Thursby-Pelham F, Neale JR, Bhandari P. A randomized controlled trial of pre-procedure simethicone and N-acetylcysteine to improve mucosal visibility during gastroscopy - NICEVIS. Endosc Int Open. 2016 Nov;4(11):E1197-E1202.

12. Keeratichananont S, Sobhonslidsuk A, Kitiyakara T, Achalanan N, Soonthornpun S. The role of liquid simethicone in enhancing endoscopic visibility prior to esophagogastrroduodenoscopy (EGD): A prospective, randomized, double-blinded, placebo-controlled trial. J Med Assoc Thai. 2010 Aug;93(8):892-7.

13. Song M, Kwek AB, Law NM, Ong JP, Tan JY, Harichander Thurairajah P, Ang DS, Ang TL. Efficacy of small-volume simethicone given at least 30 min before gastroscopy. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):572-578.

14. Ahsan M, Babaei L, Gholamrezaei A, Emami MH. Simethicone for the Preparation before Esophagogastrroduodenoscopy. Diagn Ther Endosc. 2011;2011:484532.

15. Elvas L, Areia M, Brito D, Alves S, Saraiva S, Cadime AT. Premedication with
simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double-blind randomized trial. Endoscopy. 2017 Feb;49(2):139-145.

16. Monrroy H, Vargas JI, Glasinovic E, Candia R, Azúa E, Gálvez C, Rojas C, Cabrera N, Vidaurre J, Álvarez N, González J, Espino A, González R, Parra-Blanco A. Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial. Gastrointest Endosc. 2018 Apr;87(4):986-993.

Tables

Table 1. Demographic and clinical characteristics.

|                          | Group 1 (n=110) | Group 2 (n=92) | Group 3 (n=109) |
|--------------------------|-----------------|----------------|-----------------|
| Age, years, range        | 18-88           | 22-80          | 23-84           |
| Male gender, n (%)       | 56 (50.9)       | 49 (53.3)      | 43 (39.5)       |
| Previous history of esophagogastrroduodenoscopy, n (%) | 78 (70.9)       | 53 (57.6)      | 57 (52.3)       |
| Indications, n (%)       |                 |                |                 |
| Epigastric pain          | 47 (42.7)       | 43 (46.7)      | 35 (32.0)       |
| Dyspepsia                | 13 (11.8)       | 16 (17.4)      | 39 (35.8)       |
| Nausea                   | 8 (7.3)         | 3 (3.3)        | 3 (2.8)         |
| Vomit                    | 6 (5.5)         | 2 (2.2)        | 2 (1.8)         |
| Heartburn                | 21 (19.1)       | 10 (10.9)      | 14 (12.8)       |
| Surveillance             | 15 (13.6)       | 18 (19.6)      | 16 (14.7)       |
| Positive H. pylori infection within 3 months, n (%) | 23 (20.9)       | 13 (11.8)      | 19 (17.4)       |

Table 2. Endoscopic examinations.
| Endoscopic diagnosis, n (%) | Group 1 (n=110) | Group 2 (n=92) | Group 3 (n=109) |
|-----------------------------|----------------|----------------|----------------|
| Chronic atrophic gastritis  | 6 (5.5)        | 4 [4.3]        | 10 (9.2)       |
| Chronic non-atrophic gastritis | 89 (80.9)   | 67 (72.8)      | 93 (85.3)      |
| Peptic ulcer                | 5 (4.5)        | 7 (7.6)        | 3 (2.8)        |
| Polyp                       | 9 (8.2)        | 12 (13.0)      | 3 (2.8)        |
| Carcinoma                   | 1 (0.9)        | 2 (2.2)        | 0              |

| Pathological diagnosis for biopsy, n (%) | 43 (39.1) | 59 (64.1) | 55 (50.5) |
|----------------------------------------|-----------|-----------|-----------|
| Chronic atrophic gastritis             | 4 (3.6)   | 2 (2.2)   | 4 (3.7)   |
| Chronic non-atrophic gastritis         | 22 (20.0) | 18 (19.6) | 36 (33.0) |
| Peptic ulcer                           | 4 (3.6)   | 5 (5.4)   | 9 (8.3)   |
| Adenoma                                | 9 (8.2)   | 11 (12.0) | 3 (2.8)   |
| Carcinoma                              | 1 (0.9)   | 2 (2.2)   | 0         |
| Intestinal metaplasia                  | 3 (2.7)   | 9 (9.8)   | 2 (1.8)   |
| High-grade intraepithelial neoplasm    | 0         | 5 (5.4)   | 0         |
| Low-grade intraepithelial neoplasm     | 0         | 7 (7.6)   | 1 (0.9)   |

| Examination time, min, median (range) | 8 (2-20)  | 6 (2-15)  | 9 (2-25)  |

| Gastric Cleanness Grade, n (%)        | A         | B         | C         |
|---------------------------------------|-----------|-----------|-----------|
| A                                     | 19 (17.3) | 73 (79.3) | 29 (26.6) |
| B                                     | 19 (17.3) | 12 (13.0) | 41 (37.6) |
| C                                     | 72 (65.5) | 7 (7.6)   | 39 (35.8) |

Table 3. Satisfaction score (0-10) and discomfort after examinations.
|                          | Group 1 (n=110) | Group 2 (n=92) | Group 3 (n=109) | P value |
|--------------------------|-----------------|----------------|-----------------|---------|
| **Satisfaction score, mean (range)** |                 |                |                 |         |
| Immediately after examination | 6 (3-8)         | 6 (1-10)       | 6 (1-9)         | 0.53    |
| 2h after examination      | 10 (8-10)       | 10 (10-10)     | 10 (8-10)       | 0.46    |
| **Discomfort reported, n (%)** |                |                |                 |         |
| Abdominal distension      | 38 (34.5)       | 23 (25.0)      | 29 (26.6)       | 0.26    |
| Nausea                    | 13 (11.8)       | 8 (8.7)        | 6 (5.5)         | 0.25    |
| Throat pain               | 27 (24.5)       | 2 (2.2)        | 10 (10.8)       | <0.001  |

**Figures**

![Flow chart of this study.](image)

**Figure 1**

Flow chart of this study.
Table 1: Gastric Cleanliness Grade by endoscopists

| Grade | Description                                                                 | Percentage of water and foam images |
|-------|-----------------------------------------------------------------------------|-------------------------------------|
| A     | Litter water in fundus or foam in body                                      | ≤20%                                |
| B     | Medium water or foam in fundus and/or body                                  | 20-60                               |
| C     | Debris, plenty of water or foam in fundus and/or body                       | ≥60                                 |

Figure 2

Typical images of the stomach.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

NCT03776916.pdf